Press Releases

Date Title and Summary Additional Formats
Toggle Summary Evoke Accelerates New Drug Application Process by Engaging Regulatory Experts
NDA Preparation Initiates as EVK-001 Nears Phase 3 Study Completion
View HTML
Toggle Summary Evoke Advances Commercial Preparations for EVK-001 with inVentiv Agreement
SOLANA BEACH, Calif. , July 07, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), today announced that it has entered into a master service agreement with inVentiv Commercial Services LLC ("inVentiv") in connection with Evoke's preparation for commercial activities for EVK-001, its lead
View HTML
Toggle Summary Evoke Announces Agreement with Mallinckrodt to Amend Milestone Payments
Cash runway extended to January 2019 SOLANA BEACH, Calif. , March 26, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) d­­iseases, today announced that it has amended the Company’s agreement with
View HTML
Toggle Summary Evoke Announces Discovery of Sex-Based Pharmacokinetic Differences for Gimoti™
Recent Pre-NDA Meeting Provided Guidance on Female Only NDA Filing Strategy and Post-Approval Safety Study SOLANA BEACH, Calif. , Feb. 15, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) d­­iseases, today
View HTML
Toggle Summary Evoke Announces Timing of Phase 3 Results from its Recently Fully Enrolled Pivotal Clinical Trial of EVK-001
SOLANA BEACH, Calif., May 03, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK) today announced that it expects to provide top line data results from its pivotal Phase 3 clinical trial of EVK-001 in women with symptoms associated with diabetic gastroparesis early in the third quarter of
View HTML
Toggle Summary Evoke Completes Phase 3 Clinical Trial of EVK-001 in Women with Symptoms Associated with Diabetic Gastroparesis
205 subjects complete the study
View HTML
Toggle Summary Evoke Enters Exclusive Commercial Supply Agreement for Active Pharmaceutical Ingredient in EVK-001
SOLANA BEACH, Calif., May 19, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), today announced that it has signed an exclusive commercial supply agreement with COSMA S.p.A. for the active pharmaceutical ingredient (API) in its product candidate EVK-001.
View HTML
Toggle Summary Evoke Granted First Gender Specific Patent for Gimoti™
European Union patent applies to 38 member states with expiry extended to 2032 SOLANA BEACH, Calif. , April 30, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) d­­iseases, today announced that the European
View HTML
Toggle Summary Evoke Granted Gender Specific Patent for Gimoti™ in Mexico
First North American patent for Gimoti with expiry in 2032 SOLANA BEACH, Calif. , May 10, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the Mexican Institute of Industrial
View HTML
Toggle Summary Evoke Nears Completion of Phase 3 Clinical Trial Enrollment and Secures Extension to Credit Facility
186 of 200 Subjects Enrolled in Phase 3 Clinical Trial of EVK-001
View HTML